<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TNF-α modulation &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tnf-%ce%b1-modulation/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 28 Oct 2025 16:31:38 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>TNF-α modulation &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Lenalidomide Enhances Melarsoprol-Induced cGAS-STING Immunotherapy Against Hepatocellular Carcinoma</title>
		<link>https://bioengineer.org/lenalidomide-enhances-melarsoprol-induced-cgas-sting-immunotherapy-against-hepatocellular-carcinoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 28 Oct 2025 16:31:20 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Biomimetic nanoparticle delivery]]></category>
		<category><![CDATA[cGAS-STING immunotherapy]]></category>
		<category><![CDATA[cGAS-STING pathway activation]]></category>
		<category><![CDATA[hepatocellular carcinoma immunotherapy]]></category>
		<category><![CDATA[hepatocellular carcinoma treatment]]></category>
		<category><![CDATA[Lenalidomide-Melarsoprol combination]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[TNF-α modulation]]></category>
		<category><![CDATA[Tumor microenvironment modulation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/lenalidomide-enhances-melarsoprol-induced-cgas-sting-immunotherapy-against-hepatocellular-carcinoma/</guid>

					<description><![CDATA[Hepatocellular carcinoma (HCC) stands as the predominant form of primary liver cancer and represents a formidable global health challenge, with over 680,000 new cases diagnosed every year and a staggering 620,000 fatalities. The pernicious nature of HCC is compounded by the liver’s intrinsic immunological environment, which favors immune tolerance rather than activation. This tolerance, combined [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287862</post-id>	</item>
	</channel>
</rss>
